• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 9:55:44 AM ET
    $CHFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CHFS alert in real time by email
    SC 13G/A 1 tm216476d28_sc13ga.htm SC 13G/A

     

     

     

    CUSIP No: 12542Q870    

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    CHF Solutions, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    12542Q870
    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨    Rule 13d-1(b)

    x   Rule 13d-1(c)

    ¨    Rule 13d-1(d)

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No: 12542Q870

     

    (1) NAMES OF REPORTING PERSONS
     
        CVI Investments, Inc.
     
      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)     ¨
    (b)     ¨
     
      (3) SEC USE ONLY
     
      (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
        Cayman Islands
         

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    (5) SOLE VOTING POWER
       
    0  
       
    (6) SHARED VOTING POWER **
       
    143,700
     
       
    (7) SOLE DISPOSITIVE POWER
       
    0  
       
    (8) SHARED DISPOSITIVE POWER **
       
    143,700
     

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
        143,700
       
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
        ¨
     
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
        4.9%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 12542Q870

     

    (1) NAMES OF REPORTING PERSONS
     
        Heights Capital Management, Inc.
     
      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)     ¨
    (b)     ¨
     
      (3) SEC USE ONLY
     
      (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
        Delaware
         

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    (5) SOLE VOTING POWER
       
    0  
       
    (6) SHARED VOTING POWER **
       
    143,700
     
       
    (7) SOLE DISPOSITIVE POWER
       
    0  
       
    (8) SHARED DISPOSITIVE POWER **
       
    143,700
     

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
        143,700
       
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ¨
     
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
        4.9%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 12542Q870

     

    Item 1.

     

    (a)Name of Issuer

     

    CHF Solutions, Inc. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    12988 Valley View Road, Eden Prairie, MN 55344

     

    Item 2(a).Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.0001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c).Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)Title of Class of Securities

     

    Common stock, $0.0001 par value per share

     

    Item 2(e)CUSIP Number

     

    12542Q870

     

     

     

     

    CUSIP No: 12542Q870

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of Shares issuable upon the exercise of warrants to purchase Shares (the “Warrants”). The Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 4.99%.

     

    The Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 indicates there were 2,736,060 Shares outstanding as of November 9, 2020.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

     

     

     

    CUSIP No: 12542Q870

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No: 12542Q870

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 10, 2021

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.

     

    By: Heights Capital Management, Inc.   By: /s/ Brian Sopinsky
     pursuant to a Limited Power of   Name: Brian Sopinsky
    Attorney, a copy of which was   Title: Secretary
    previously filed      

     

    By: /s/ Brian Sopinsky    
    Name: Brian Sopinsky    
    Title: Secretary    

     

     

     

     

    CUSIP No: 12542Q870

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*

     

    *Previously filed

     

     

     

    Get the next $CHFS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CHFS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CHFS
    SEC Filings

    See more
    • CHF Solutions, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Nuwellis, Inc. (0001506492) (Filer)

      4/27/21 8:15:21 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEF 14A filed by CHF Solutions, Inc.

      DEF 14A - CHF Solutions, Inc. (0001506492) (Filer)

      4/13/21 4:43:22 PM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CHF Solutions, Inc. filed SEC Form 8-K: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers

      8-K - CHF Solutions, Inc. (0001506492) (Filer)

      4/5/21 5:16:56 PM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    Leadership Updates

    Live Leadership Updates

    See more
    • Nuwellis Announces New Appointments to Leadership Team

      EDEN PRAIRIE, Minn., June 22, 2021 (GLOBE NEWSWIRE) -- Continuing its dynamic growth in support of its commitment to expanding access to life-saving ultrafiltration therapies for adult and pediatric patients suffering from fluid overload, Nuwellis, Inc. (NASDAQ:NUWE), formerly CHF Solutions, Inc., today announced the appointment of George Montague as Chief Financial Officer, effective June 28, 2021. Neil P. Ayotte, Esq. also joined the Company as Senior Vice President, General Counsel, Secretary and Chief Compliance Officer on June 7, 2021. "Nuwellis is entering an energizing new phase with significant opportunities in heart failure, pediatrics and critical care. The deep knowledge and ex

      6/22/21 8:00:00 AM ET
      $NUWE
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CHF Solutions Appoints Nestor Jaramillo, Jr. as President and Chief Executive Officer

      EDEN PRAIRIE, Minn., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the appointment of President and Chief Operating Officer Nestor Jaramillo, Jr. to President and Chief Executive Officer (CEO), effective immediately. Predecessor CEO John Erb will continue to serve as the company’s Chairman of the Board. Mr. Jaramillo joined CHF Solutions in May 2019 and has driven the evolution of the company’s therapeutic focus strategy from solely heart failure to an expansion into critical care and pediatrics. His vision to transform the trajectory of cardiorenal disea

      1/19/21 8:00:00 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by Wotta Paul

      3 - CHF Solutions, Inc. (0001506492) (Issuer)

      4/16/21 11:12:05 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by L John Erb

      4 - CHF Solutions, Inc. (0001506492) (Issuer)

      1/26/21 9:23:33 PM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by P. Thomas Lynch

      4 - CHF Solutions, Inc. (0001506492) (Issuer)

      1/26/21 9:22:39 PM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CHFS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Nuwellis to Advance Treatment of Critically-Ill Children and Babies Under $1.7 Million NIH Grant

      EDEN PRAIRIE, Minn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Critically-ill children and babies with kidney failure or who are dependent on artificial kidney support currently do not have enough therapeutic options. Nuwellis (NASDAQ:NUWE) plans to fill this unmet need with the development of a fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for small babies and children. Nuwellis is a medical device company dedicated to transforming care for patients suffering from fluid imbalance. The new device will build on the existing technology of the company's Aquadex SmartFlow® system, and will be funded in part by a $1.7 million grant from the Nati

      8/5/21 8:00:00 AM ET
      $NUWE
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis, Inc. To Announce Second Quarter 2021 Financial Results on August 10, 2021

      EDEN PRAIRIE, Minn., July 27, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), announced today that its second quarter 2021 financial results will be released on Tuesday, August 10, 2021. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. To access the live webcast, please visit the Investors page of the Nuwellis website at http://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 1396749. An audio archive of the webcast will be available following

      7/27/21 4:03:00 PM ET
      $CHFS
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • American Medical Association Issues New CPT Code for Nuwellis' Aquadex Ultrafiltration

      EDEN PRAIRIE, Minn., July 13, 2021 (GLOBE NEWSWIRE) -- In an effort to increase the availability of life-saving ultrafiltration therapy to people experiencing fluid overload, the American Medical Association (AMA) has issued a new Category III Current Procedural Terminology (CPT®) code, 0692T for Therapeutic Ultrafiltration. The new CPT code will come into effect on January 1, 2022, at which time providers can utilize the code when using Aquadex® to deliver ultrafiltration to adults and children (20 kg or more). Aquadex is developed and marketed by Nuwellis, Inc. (NASDAQ:NUWE). A specific code for ultrafiltration was granted after a thorough review and validation that the technology met t

      7/13/21 8:00:00 AM ET
      $NUWE
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by CHF Solutions, Inc.

      SC 13G - CHF Solutions, Inc. (0001506492) (Subject)

      3/24/21 11:03:40 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by CHF Solutions, Inc.

      SC 13G - CHF Solutions, Inc. (0001506492) (Subject)

      3/23/21 8:52:19 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - CHF Solutions, Inc. (0001506492) (Subject)

      2/16/21 9:55:44 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    Financials

    Live finance-specific insights

    See more
    • Nuwellis, Inc. To Announce Second Quarter 2021 Financial Results on August 10, 2021

      EDEN PRAIRIE, Minn., July 27, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), announced today that its second quarter 2021 financial results will be released on Tuesday, August 10, 2021. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. To access the live webcast, please visit the Investors page of the Nuwellis website at http://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 1396749. An audio archive of the webcast will be available following

      7/27/21 4:03:00 PM ET
      $CHFS
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care